ATE354361T1 - Neue verwendung von prodigiosin zur behandlung von diabetes mellitus - Google Patents

Neue verwendung von prodigiosin zur behandlung von diabetes mellitus

Info

Publication number
ATE354361T1
ATE354361T1 AT00952026T AT00952026T ATE354361T1 AT E354361 T1 ATE354361 T1 AT E354361T1 AT 00952026 T AT00952026 T AT 00952026T AT 00952026 T AT00952026 T AT 00952026T AT E354361 T1 ATE354361 T1 AT E354361T1
Authority
AT
Austria
Prior art keywords
prodigiosin
diabetes mellitus
treatment
new use
treat
Prior art date
Application number
AT00952026T
Other languages
English (en)
Inventor
Hwanmook Kim
Sangbae Han
Changwoo Lee
Kihoon Lee
Sehyung Park
Youngkook Kim
Original Assignee
Korea Res Inst Of Bioscience
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Res Inst Of Bioscience filed Critical Korea Res Inst Of Bioscience
Application granted granted Critical
Publication of ATE354361T1 publication Critical patent/ATE354361T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT00952026T 2000-02-15 2000-08-10 Neue verwendung von prodigiosin zur behandlung von diabetes mellitus ATE354361T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020000007139A KR20010081515A (ko) 2000-02-15 2000-02-15 프로디지오신의 당뇨병 예방 및 치료용 조성물

Publications (1)

Publication Number Publication Date
ATE354361T1 true ATE354361T1 (de) 2007-03-15

Family

ID=19646694

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00952026T ATE354361T1 (de) 2000-02-15 2000-08-10 Neue verwendung von prodigiosin zur behandlung von diabetes mellitus

Country Status (7)

Country Link
US (1) US6638968B1 (de)
EP (1) EP1251847B1 (de)
KR (2) KR20010081515A (de)
AT (1) ATE354361T1 (de)
AU (1) AU6479000A (de)
DE (1) DE60033569T2 (de)
WO (1) WO2001060361A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014987A1 (en) * 2000-01-26 2004-01-22 Gemin X Biotechnologies Inc. Pyrrole-Type compounds, compositions, and methods for treating cancer or viral diseases
KR100392225B1 (ko) * 2001-04-19 2003-07-22 한국생명공학연구원 류머티스 관절염 치료용 프로디지오신 조성물
ES2304135T3 (es) * 2001-07-18 2008-09-16 Gemin X Biotechnologies Inc. Compuestos tipo pirrol, composiciones y metodos para tratar el cancer, tratar enfermedades virales y causar inmunosupresion.
DE102013006341A1 (de) 2013-04-15 2014-10-16 Yoen Ok Roth Pharmazeutisches Erzeugnis zur Behandlung von Augenerkrankungen
US10654801B2 (en) 2016-04-08 2020-05-19 Institute For Cancer Research Prodigiosin analogs
US10870640B2 (en) 2016-04-08 2020-12-22 Institute For Cancer Research Prodigiosin analogs and methods of use
KR101995768B1 (ko) * 2019-03-13 2019-07-03 (주)엔솔바이오사이언스 신규 펩타이드 및 그 용도

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9326284D0 (en) * 1993-12-23 1994-02-23 Erba Carlo Spa Pyrrolydenemethyl-derivatives and process for their preparation
GB9603212D0 (en) * 1996-02-15 1996-04-17 Pharmacia Spa Process for the preparation of 2,2'-bipyrrolyl-pyrromethane derivatives
KR100252197B1 (ko) 1997-09-20 2000-04-15 박호군 세라시아 마르세센스 균주의 배양액으로 부터 분리한 면역억제제용 프로디지오신
GB9802745D0 (en) * 1998-02-09 1998-04-08 Pharmacia & Upjohn Spa Benzyloxy prodigiosine compounds

Also Published As

Publication number Publication date
DE60033569D1 (de) 2007-04-05
EP1251847A1 (de) 2002-10-30
US6638968B1 (en) 2003-10-28
AU6479000A (en) 2001-08-27
DE60033569T2 (de) 2007-10-31
KR20010108108A (ko) 2001-12-07
KR100406848B1 (ko) 2003-11-21
EP1251847A4 (de) 2004-11-10
EP1251847B1 (de) 2007-02-21
KR20010081515A (ko) 2001-08-29
WO2001060361A1 (en) 2001-08-23

Similar Documents

Publication Publication Date Title
DE60101669T2 (de) Verwendung von botulinum-toxin zur behandlung von diabetes
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
ATE544449T1 (de) Neue verwendung von peptidverbindungen zur behandlung von amyothropher lateralsklerose
ATE254461T1 (de) Behandlung von augenschmerzen
DE60019158D1 (de) Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien
ATE428413T1 (de) Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen
ATE303147T1 (de) Verwendung von thiazolidinedion-derivaten zur behandlung des polyzystischen ovarien syndroms und des schwangerschaftsdiabetes
ATE238792T1 (de) Verwendung von makroliden zur behandlung von glaukom
ATE435026T1 (de) Verfahren zur prävention und behandlung von diabetes mit neurturin
DE60222745D1 (de) Verwendung von neurofilamentproteinen zur behandlung von tumoren
ATE402699T1 (de) Verwendung von substituierten pyrazolen zur behandlung von allergien
DE60033569D1 (de) Neue verwendung von prodigiosin zur behandlung von diabetes mellitus
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
ATE402694T1 (de) Verwendung von 1-phenyl-3-dimethylamino-propan- verbindungen zur therapie der harninkontinenz
ATE361071T1 (de) Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie
ATE361755T1 (de) Verwendung von thrombomodulinanaloga zur regenerierung von rückenmarkverletzungen
EP1056458A4 (de) Methoden zur behandlung von schmerzen, einscliesslich chronischen und frauenspezifischen schmerzen
DE60213365D1 (de) Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen
DE69623767D1 (de) Verwendung von pyrrolidinderivaten zur behandlung des alkoholismus
ATE337004T1 (de) Verwendung von mangafodipir zur behandlung der hepatozellularen insuffizienz
DE69504717D1 (de) Behandlung von organischen Verbindungen zur Reduzierung des Chlorgehaltes
ATE228840T1 (de) Neue verwendung von ropivacain zur schmerzbehandlung
ATE273013T1 (de) Verwendung von simethicone zur behandlung der ulzerativen kolitis
DE60124093D1 (de) S-methyl-dihydro-ziprasidon zur Behandlung von Augenerkrankungen.
ATE291434T1 (de) Verwendung von angiotensin zur behandlung von krebsmetastasierung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties